肿瘤可能如何抵御 γδ T 细胞攻击。
How tumors might withstand γδ T-cell attack.
机构信息
INSERM UMR1037, Cancer Research Center of Toulouse, Toulouse, France.
出版信息
Cell Mol Life Sci. 2011 Jul;68(14):2433-42. doi: 10.1007/s00018-011-0705-7. Epub 2011 May 6.
Abstract
Several clinical trials are currently assessing the therapeutic activity of human TCRVγ9Vδ2(+) lymphocytes in cancer. Growing tumors usually follow a triphasic "Elimination, Equilibrium, Escape" evolution in patients. Thus, at diagnostic, most tumors have already developed some means to escape to immune protection. We review here the conventional immunoescape mechanisms which might also protect against cytolytic TCRVγ9Vδ2(+) lymphocytes activated by phosphoantigens. Neutralization of these deleterious processes might prove highly valuable to improve the efficacy of ongoing γδ cell-based cancer immunotherapies.
摘要
目前有几项临床试验正在评估人类 TCRVγ9Vδ2(+)淋巴细胞在癌症中的治疗活性。生长中的肿瘤通常会在患者中经历一个三阶段的“消除、平衡、逃逸”演变。因此，在诊断时，大多数肿瘤已经发展出一些逃避免疫保护的手段。我们在这里回顾了常规的免疫逃逸机制，这些机制也可能对抵抗磷酸抗原激活的细胞毒性 TCRVγ9Vδ2(+)淋巴细胞起到保护作用。中和这些有害过程可能对提高正在进行的基于γδ细胞的癌症免疫疗法的疗效非常有价值。
相似文献
1
How tumors might withstand γδ T-cell attack.肿瘤可能如何抵御 γδ T 细胞攻击。
Cell Mol Life Sci. 2011 Jul;68(14):2433-42. doi: 10.1007/s00018-011-0705-7. Epub 2011 May 6.
2
Pitfalls on the roadmap to gammadelta T cell-based cancer immunotherapies.基于 gammadelta T 细胞的癌症免疫疗法道路上的陷阱。
Immunol Lett. 2009 May 14;124(1):1-8. doi: 10.1016/j.imlet.2009.03.011. Epub 2009 Mar 31.
3
γδ T cells in cancer immunotherapy.癌症免疫疗法中的γδ T细胞。
Oncotarget. 2017 Jan 31;8(5):8900-8909. doi: 10.18632/oncotarget.13051.
4
BTN3A1-antibodies and phosphoantigens: TCRVγ9Vδ2 "see" the difference.BTN3A1抗体与磷酸化抗原：TCRVγ9Vδ2“识别”差异。
Eur J Immunol. 2017 Jun;47(6):954-957. doi: 10.1002/eji.201747058.
5
The subtle interplay between gamma delta T lymphocytes and dendritic cells: is there a role for a therapeutic cancer vaccine in the era of combinatorial strategies?γδ T 淋巴细胞与树突状细胞之间的微妙相互作用：在联合策略的时代，治疗性癌症疫苗是否有作用？
Cancer Immunol Immunother. 2021 Jul;70(7):1797-1809. doi: 10.1007/s00262-020-02805-3. Epub 2021 Jan 1.
6
γδ T-APCs: a novel tool for immunotherapy?γδ T-APCs：免疫治疗的新工具？
Cell Mol Life Sci. 2011 Jul;68(14):2443-52. doi: 10.1007/s00018-011-0706-6. Epub 2011 May 15.
7
Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors.唑来膦酸激活的 Vγ9γδ T 细胞免疫治疗是可行的，并恢复了实体瘤患者 γδ T 细胞的损伤。
Cytotherapy. 2011 Jan;13(1):92-7. doi: 10.3109/14653249.2010.515581. Epub 2010 Sep 10.
8
Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside.基于 Vγ9Vδ2 T 细胞的免疫疗法治疗血液系统恶性肿瘤：从基础到临床。
Cell Mol Life Sci. 2011 Jul;68(14):2419-32. doi: 10.1007/s00018-011-0704-8. Epub 2011 May 17.
9
γδ cells and tumor microenvironment: A helpful or a dangerous liason?γδ 细胞与肿瘤微环境：有益还是危险的联络？
J Leukoc Biol. 2018 Mar;103(3):485-492. doi: 10.1002/JLB.5MR0717-275RR. Epub 2017 Dec 14.
10
Human γδ T-cell responses in infection and immunotherapy: common mechanisms, common mediators?人类 γδ T 细胞在感染和免疫治疗中的反应：共同机制，共同介质？
Eur J Immunol. 2012 Jul;42(7):1668-76. doi: 10.1002/eji.201242492.
引用本文的文献
1
Function and Spatial Organization of Tumor-Invasive Human γδ T Cells-What Do We Know?肿瘤浸润性人类γδ T细胞的功能与空间组织——我们了解多少？
Eur J Immunol. 2025 Jan;55(1):e202451075. doi: 10.1002/eji.202451075. Epub 2024 Dec 2.
2
Vdelta1 T cells are more resistant than Vdelta2 T cells to the immunosuppressive properties of galectin-3.Vdelta1 T 细胞比 Vdelta2 T 细胞更能抵抗半乳糖凝集素-3 的免疫抑制特性。
Front Immunol. 2024 Jan 8;14:1286097. doi: 10.3389/fimmu.2023.1286097. eCollection 2023.
3
Vγ9Vδ2 T-cell immunotherapy in blood cancers: ready for prime time?γ9δ2 T 细胞免疫疗法治疗血液肿瘤：是否已准备好进入黄金时代？
Front Immunol. 2023 Apr 18;14:1167443. doi: 10.3389/fimmu.2023.1167443. eCollection 2023.
4
Boosting γδ T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma.通过阻断程序性死亡受体1增强滤泡性淋巴瘤中γδ T细胞介导的抗体依赖性细胞毒性作用
Oncoimmunology. 2018 Dec 17;8(3):1554175. doi: 10.1080/2162402X.2018.1554175. eCollection 2019.
5
γδ T Cells and Tumor Microenvironment: From Immunosurveillance to Tumor Evasion.γδ T细胞与肿瘤微环境：从免疫监视到肿瘤逃逸
Front Immunol. 2018 Jun 15;9:1395. doi: 10.3389/fimmu.2018.01395. eCollection 2018.
6
Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells.白细胞介素-15增强人γδT细胞的增殖、刺激表型和抗肿瘤效应功能。
J Hematol Oncol. 2016 Sep 29;9(1):101. doi: 10.1186/s13045-016-0329-3.
7
Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy.通过基于树突状细胞的免疫疗法增强γδ T细胞的抗肿瘤免疫力。
Oncoimmunology. 2015 Apr 1;4(8):e1021538. doi: 10.1080/2162402X.2015.1021538. eCollection 2015 Aug.
8
The PPARα pathway in Vγ9Vδ2 T cell anergy.Vγ9Vδ2 T细胞无反应性中的PPARα信号通路。
Cell Mol Biol Lett. 2014 Dec;19(4):649-58. doi: 10.2478/s11658-014-0218-0. Epub 2014 Nov 25.
9
Induction of ATM/ATR pathway combined with Vγ2Vδ2 T cells enhances cytotoxicity of ovarian cancer cells.诱导 ATM/ATR 通路并联合 Vγ2Vδ2 T 细胞可增强卵巢癌细胞的细胞毒性。
Biochim Biophys Acta. 2014 Jul;1842(7):1071-9. doi: 10.1016/j.bbadis.2014.04.003. Epub 2014 Apr 13.
10
Regulation of development of CD56 bright CD11c + NK-like cells with helper function by IL-18.IL-18对具有辅助功能的CD56明亮CD11c + NK样细胞发育的调节作用
PLoS One. 2013 Dec 20;8(12):e82586. doi: 10.1371/journal.pone.0082586. eCollection 2013.
本文引用的文献
1
Phosphoantigens overcome human TCRVgamma9+ gammadelta Cell immunosuppression by TGF-beta: relevance for cancer immunotherapy.磷酸抗原通过 TGF-β克服人 TCRVγ9+γδ T 细胞免疫抑制：与癌症免疫治疗的相关性。
J Immunol. 2010 Jun 15;184(12):6680-7. doi: 10.4049/jimmunol.1000681. Epub 2010 May 17.
2
PGE2 inhibits natural killer and gamma delta T cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling.PGE2 通过 cAMP 介导的 PKA 型 I 依赖性信号通路抑制 NKR 和 TCR 触发的自然杀伤细胞和 γδ T 细胞细胞毒性。
Biochem Pharmacol. 2010 Sep 15;80(6):838-45. doi: 10.1016/j.bcp.2010.05.002. Epub 2010 May 12.
3
A regulatory cross-talk between Vgamma9Vdelta2 T lymphocytes and mesenchymal stem cells.Vγ9Vδ2 T淋巴细胞与间充质干细胞之间的调节性相互作用。
Eur J Immunol. 2009 Mar;39(3):752-62. doi: 10.1002/eji.200838812.
4
Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells.人间充质干细胞与γδT细胞或不变自然杀伤T细胞之间的相互作用
Stem Cells. 2009 Mar;27(3):693-702. doi: 10.1634/stemcells.2008-0687.
5
CD4+ CD25(high) Foxp3+ regulatory T cells downregulate human Vdelta2+ T-lymphocyte function triggered by anti-CD3 or phosphoantigen.CD4+ CD25（高表达）Foxp3+调节性T细胞下调由抗CD3或磷酸抗抗原触发的人Vδ2+ T淋巴细胞功能。
Immunology. 2009 Jul;127(3):398-407. doi: 10.1111/j.1365-2567.2008.02982.x. Epub 2008 Nov 14.
6
Phosphoantigen-activated V gamma 2V delta 2 T cells antagonize IL-2-induced CD4+CD25+Foxp3+ T regulatory cells in mycobacterial infection.磷酸抗原激活的Vγ2Vδ2 T细胞在分枝杆菌感染中对抗白细胞介素-2诱导的CD4⁺CD25⁺Foxp3⁺调节性T细胞。
Blood. 2009 Jan 22;113(4):837-45. doi: 10.1182/blood-2008-06-162792. Epub 2008 Nov 3.
7
Mesenchymal stem cell-like cells derived from human gastric cancer tissues.源自人胃癌组织的间充质干细胞样细胞。
Cancer Lett. 2009 Feb 8;274(1):61-71. doi: 10.1016/j.canlet.2008.08.036. Epub 2008 Oct 11.
8
Inhibition of phosphoantigen-mediated gammadelta T-cell proliferation by CD4+ CD25+ FoxP3+ regulatory T cells.CD4+ CD25+ FoxP3+调节性T细胞对磷酸抗抗原介导的γδT细胞增殖的抑制作用。
Immunology. 2009 Feb;126(2):256-67. doi: 10.1111/j.1365-2567.2008.02894.x. Epub 2008 Sep 2.
9
VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma.间充质干细胞的血管内皮生长因子表达有助于胰腺癌的血管生成。
Br J Cancer. 2008 Aug 19;99(4):622-31. doi: 10.1038/sj.bjc.6604508. Epub 2008 Jul 29.
10
How regulatory T cells work.调节性T细胞的工作方式。
Nat Rev Immunol. 2008 Jul;8(7):523-32. doi: 10.1038/nri2343.
Zotero 插件